Hanwa Memorial Hospital

Recent papers from Hanwa Memorial Hospital

1. Multisystem disease accumulation in routine claims reveals dynamic multimorbidity and mortality risk in older adults: a multicentre retrospective cohort study2026
2. Effects of low-dose dapagliflozin on heart failure–related outcomes in patients with heart failure and type 2 diabetes: a subanalysis of the dapper studyEuropean Heart Journal · 2026
3. Dynamic Changes in Metabolic Syndrome and Risk of Hepatocellular Carcinoma: Evidence From a Nationwide Japanese CohortLiver international communications. · 2026
4. Effect of Low-Intensity Transcranial Focused Ultrasound Stimulation on Neuropathic Pain: Protocol for a Randomized, Single-Blind, Placebo-Controlled, 3-Arm, Parallel-Group TrialJMIR Research Protocols · 2026
5. Early rehabilitation initiation after aneurysmal subarachnoid haemorrhage: evaluation of mortality and functional outcomesEuropean Stroke Journal · 2026
6. MCL-1 as a tumor microenvironment-linked survival node in cholangiocarcinomaFrontiers in Oncology · 2026
7. Baseline DCP May Modify Response to Atezolizumab‐Bevacizumab Versus Durvalumab‐Tremelimumab in Unresectable HCCLiver International · 2026
8. Simplified BALAD (BALAD‐S) Score as a Guide for First‐Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular CarcinomaHepatology Research · 2026
9. Ruptured cerebral arteriovenous malformation associated with enlarged parietal foramina: a rare surgical case with pathogenetic implicationsChild s Nervous System · 2026
10. An interpretable combinatorial data-mining framework for predicting new-onset hypertension in the general populationHypertension Research · 2026
11. Two Cases of Innominate Artery Stenting via Alternative Upper-Extremity Arterial Access Using Tailored Distal Protection StrategiesJournal of Neuroendovascular Therapy · 2026
12. An internet–based survey on the definition of ShibirePAIN RESEARCH · 2026
13. Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real‐World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA TrialJournal of Gastroenterology and Hepatology · 2026
14. Optimizing treatment strategies for femoral neck fractures using a machine learning modelJournal of Orthopaedic Surgery and Research · 2026
15. Ablation‐Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular CarcinomaHepatology Research · 2026
16. Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world studyHepatology · 2026
17. Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus BevacizumabHepatology Research · 2026
18. Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus BevacizumabHepatology Research · 2026
19. Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular CarcinomaLiver international communications. · 2026
20. Effect of Butyrate‐Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and TremelimumabJGH Open · 2026